ClinicalTrials.gg
Status unknownNCT03364829Updated Apr 30, 2018

Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program

A Phase 4 interventional study of Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease, sponsored by Taipei Medical University Shuang Ho Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-30.

Sponsored by Taipei Medical University Shuang Ho Hospital · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jan 2016, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. indacaterol · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
42nd of 57
50 · median 154
Started
2016
with 1 other
Phase 4
20 of 57
none open now
Registered
55th of 57
by date
Lead sponsor
1 of 57
Taipei Medical University Shuang Ho Hospital

Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, this one is the 42nd largest by planned enrollment, is one of 2 that started in 2016, is one of 20 in phase 4, and was the 55th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About indacaterol

indacaterol: first FDA approval 2011 (ARCAPTA NEOHALER), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The effectiveness of combined bronchodilator and exercise training on improving exercise capacity has been reported in COPD. However, little is known about effect of respective treatment in a real-time monitoring. Investigators applied wearable devices in monitoring continuously in COPD patients under treatment of combined dual bronchodilator and exercise training and research on associated inflammatory biomarkers profiles change

Read the detailed description

The prevalence of chronic obstructive pulmonary disease (COPD) has increased year by year and the estimated mortality rate by 2030 will be in the fourth place. Estimated global prevalence of COPD in the population over age 40 is about 9-10% of the population. In Taiwan, the prevalence is about 16%. COPD is characteristic of irreversible airflow obstruction due to the pathological changes in the small airways, lung parenchyma and pulmonary vessels with chronic inflammation of the specific immune cells, as well as structural changes.

Although studies have suggested that exercise training in patients with COPD benefit the physical activity, but the anti-inflammatory benefits is unknown.Consider individual needs, this study will use the home mobile coach from Dr. Liu domestic development program to further investigate chronic obstructive pulmonary disease patients after receiving this training program,performance and analysis in the clinical laboratory to explore anti-inflammatory and pro-inflammatory between relevance and mechanisms in patients with COPD under real-time wearable devices monitoring

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) according to diagnostic criteria of (age ≧ 40 years old and ≦ 85 years old), that the use of post-bronchodilator inhalation, pulmonary function test results of the forced expiratory volume first second (.0) / forced vital capacity (FVC) \<70% 2. COPD patients is not currently accepting any pulmonary rehabilitation program 3. Currently in a stable condition, after researchers explained the purpose of this study, the researchers agreed to participate.

Exclusion criteria

Exclusion Criteria:

  1. Asthma, bronchiectasis, tuberculosis, pneumoconiosis, or other pulmonary diseases
  2. Associated with neuromuscular function disorders such as hemiplegia or no independent walking function;
  3. Severe heart disease, such as acute myocardial infarction, serious or heart failure, etc.
  4. Diagnosed with severe mental disorders such as dementia or poor compliance
  5. Acute exacerbation or infection in 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    COPD on Indacaterol/Glycopyrronium

    COPD on indacaterol/glycopyrronium for 1 month

    Drug: Indacaterol/Glycopyrronium

Interventions

06

What researchers measure

Primary outcomes

  1. Combined dual bronchodilator and protocolized pulmonary rehabilitation effect on daily activity in step counts per 24 hours

    Change from baseline daily activity in step counts per 24 hours at 1 month after dual bronchodilator therapy and at 4th month after further combined dual bronchodilator with protocolized pulmonary rehabilitation therapy for 3 months. Daily step counts measured by wearable devices was represented for daily activity

    Time frame: Investigators would measured daily step counts for each patients at baseline, 1 month and 4th month after intervention

  2. Combined dual bronchodilator and protocolized pulmonary rehabilitation effect on 6 minutes walking distance in meters

    Change from baseline 6 minutes walking distance in meters at 1 month after dual bronchodilator therapy and at 4th month after further combined dual bronchodilator with protocolized pulmonary rehabilitation therapy for 3 months.

    Time frame: Investigators would measured daily steps for each patients at baseline, 1 month and 4th month after intervention

  3. Combined dual bronchodilator and protocolized pulmonary rehabilitation effect on heart rate variability

    Change from baseline heart rate variability in ratio of low frequency and high frequency at 1 month after dual bronchodilator therapy and at 4th month after further combined dual bronchodilator with protocolized pulmonary rehabilitation therapy for 3 months.

    Time frame: Investigators would measured heart rate variability in ratio of low frequency and high frequency for each patients at baseline, 1 month and 4th month after intervention

07

Study locations

1 of 1 sites recruiting
  • Taipei Medical University-Shuang Ho Hospital
    Taipei, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2016 (actual). Primary completion is estimated for Apr 2018, 27 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 27 months is close to that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2017
First posted
Dec 7, 2017
StartActual
Jan 1, 2016
Primary completionEst.
Apr 30, 2018
CompletionEst.
Jun 30, 2018
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03364829
Responsible party
Kuan Yuan Chen (Attending Physician of pulmonary medicine, Taipei Medical University Shuang Ho Hospital) — Principal investigator
First posted
Dec 7, 2017
Start date
Jan 1, 2016
Primary completion
Apr 30, 2018 (estimated)
Completion
Jun 30, 2018 (estimated)
Last update
Apr 30, 2018

Study contacts

Kuan-Yuan Chen
Contact
a112378633@gmail.com
Kang-Yuan Lee
Contact
13258@s.tmu.edu.tw
Kang-Yuan Lee
principal investigator · Taipei Medical University Shuang Ho Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Indacaterol · Glycopyrrolate

Start the discussion